Introduction
Cell therapy has progressively become an important modality of regenerative medicine. Through the use of now classical cell types, such as hematopoietic stem cells, skin or cartilage progenitors, pancreatic islets, cell therapy has entered the therapeutic armamentarium for dedicated diseases, and should be completed in the future by new emerging adult, embryonic or induced pluripotent stem cells. In the specific clinical field of muscular disorders, clinical and social expectations are high. Autologous approaches are being developed when localized repairs are mandated, whereas heterologous approaches are used in the context of generalized advanced degenerative diseases. 1 Whatever be the immunological situation, however, biological, conceptual and technical set-up of strategies have been hampered by several issues, and particularly in large organisms. 2 Several major obstacles remain to be abated: the amount of tissues to be treated may represent dozens of kilograms; immediate cell death post-injection may exceed 80%; grafted cell migration and colonization of target muscles are extremely limited. Nevertheless, transplantation of myoblasts has been considered as a possible therapeutic approach for several pathologies such as Duchenne muscular dystrophy, 3 heart failure 4 and urinary incontinence. 5 Moreover, myoblasts are not the only candidates for muscular cell therapy approaches. Mesoangioblasts, 6 pericytes 7 or CD133-positive cells 8 have also been proposed. The efficacy of these different approaches has to be improved and so requires the development of follow-up and evaluation tools.
When new ideas and possible technical improvements are to be tested, there is a great need for non-invasive imaging techniques that would allow the mapping of therapeutic cell distribution in the organs, the detection of apoptotic and necrotic cells, the measurement of cell migration and fusion with muscle fibers, the determination of cell proliferation and survival. 2 All this information would be of invaluable help to select and optimize procedures, without having to kill multiple groups of animals or having to perform multiple biopsies on the same individuals over a period of time to determine event kinetics.
In this context, 1 H-NMR (nuclear magnetic resonance) imaging might have a role to play to evaluate the gross response of muscles to cell therapy: is there a gain in muscle mass? Are fibrosis and fatty degeneration volume fractions decreased? With current technologies, the amount of therapeutic cells transferred into skeletal muscle represents a very small percentage of the recipient cell population. This implies that imaging techniques used to monitor organ response must be of high resolution and high precision, which NMR imaging can offer today. Although conventional histological and physiological analyses have demonstrated myoblast transfer efficiency, [9] [10] [11] [12] there have so far been no NMR studies reporting changes in muscle mass or composition after myoblast transplantation.
In most instances, one might prefer to directly visualize the grafted cells in vivo. With NMR as with all other available imaging techniques, there is no intrinsic contrast between transplanted cells and host tissues when they are of identical nature, as in this case, with myoblasts among muscle fibers (J-TV, unpublished data). To distinguish the transplanted cells in the target organ, they need to be labeled prior to injection. In nuclear medicine, they are typically labeled with 111 In-oxime or 99 Tcm. [13] [14] [15] Contrast agents (CAs) are available for NMR imaging. Two main classes of CAs are commonly used for clinical diagnostic MRI: the lanthanide-based paramagnetic complexes and the superparamagnetic iron oxide particles (SPIOs). They differ from each other not only by the nature and mechanisms of the contrast generated but also by their molecular size and biodistribution. 16 Both classes were developed for i.v. injection but, whereas lanthanide chelates distribute exclusively in the extracellular space in normal conditions, the high molecular weight SPIOs are rapidly taken up by reticulo-histiocytic cells and have been used to track these specific cell types in vivo, including macrophages, for many years. 17 They were subsequently successfully tested for in vitro cell loading prior to in vivo injection. 18 Although internalization pathways and long-term intracellular behavior of these molecules are not yet fully understood, it is well established that intracellular loading with these CAs is possible without significant impact on cell viability or function. 19, 20 Accurate evaluation and monitoring of cell therapy protocols require a very sensitive technique, because of the small amount of injected therapeutic cells. For these reasons, SPIOs, which have very high T2 (and T2*) relaxivities, have been privileged over the past 10 years. The high susceptibility difference between CA and surrounding tissue can be exploited to generate a negative contrast, and several studies have indeed demonstrated that SPIO labeling allows the detection of grafted cells in vivo with high sensitivity. 21, 22 A serious issue is the particulate nature of SPIOs, which make them a target for phagocytosis by activated reticulo-histiocytic cells. SPIOs have sizes ranging from 120 to 180 nm. If they are released from damaged or dying cells, there is a high probability that they will be rapidly phagocytosed by macrophages. This would result in false-positive images, indicating the persistence of grafted cells, whereas it is really inflammatory cells that are detected instead. This problem was recognized and nicely documented by Cahill et al. 22 But the caveat seems, however, to have been ignored by most investigators so far.
Recently, gadolinium (Gd) chelates have also been investigated as CA for cell labeling. 20, 23, 24 Grafted on Matrigel structures and subcutaneously implanted, endothelial progenitor cells labeled with Gd-HPDO3A were identified as hyperintensities 14 days after injection. 20 Plugged in mouse kidney, they were visible 24 h after injection. The authors demonstrated the possibility of using Gd chelates for cell monitoring, at least in tissues with low intrinsic NMR signal such as kidney and suggested that it might be tested in muscle. Indeed, the figures of CA relaxivities are more in favor of SPIOs than Gd chelates, with a potential negative impact on detection sensitivity. However quantitation issues are likely to be less problematic because Gd chelate contrast is based mainly on T1 changes, which are much more proportional to CA concentrations and hence easier to treat analytically.
Very interestingly, after i.v. injection, low molecular weight Gd chelates are rapidly eliminated through glomerular filtration, with a blood half-life shorter than 30 min. 25, 26 Similarly, lanthanide-based CAs, which are released in the interstitium in the case of labeled cell death, also ought to be rapidly cleared by the kidney. With this class of CA, label recapture by other cells can be expected to be less of a problem than with SPIOs.
The aim of this study was to test this hypothesis in skeletal muscle, and to investigate and compare the ability of Gd-DTPA and SPIOs to accurately report the fate of labeled human myoblasts in the case of high cell death rate after transplantation. We carried out cell labeling and transplant experiments with two molecules in parallel, one representative of each class of CA. Wildtype mice were used as transplant recipients of human cells to take advantage of the massive and rapid immunorejection induced and the very high and rapid death rates of transplanted cells. 27 Immunohistochemical analyses were confronted with the NMR measurements and provided a reference frame for correct interpretation of the in vivo imaging data.
Results

In vitro assessment of loading conditions
We determined the effective concentration ranges for each of the CAs.
First, their potential cellular toxicity was evaluated in vitro. Gd-DTPA and SPIOs were incubated for 24 h with the human myoblasts in the concentration ranges of 10-80 mM and of 10-1000 mg ml
À1
, respectively. Nonspecific endocytosis and pinocytosis mechanisms warrant penetration of these agents into the cells, which are concentrated in endosomes and lysosomes, and stored in the cytosol. 19, 28 Immediate cell death and induction of apoptosis were quantified by flow cytometric evaluation of propidium iodide uptake and annexin V surface expression, respectively. As compared with unloaded cells, the increase in death rate was statistically significant for the highest concentrations only (60 and 80 mM of Gd-DTPA; 700 and 1000 mg ml À1 of SPIOs; Po0.05, n ¼ 4). The apoptosis rate tended to increase with concentrations without being significant below 80 mM of Gd-DTPA (Po0.05, n ¼ 4).
Second, the proliferation characteristics of myogenic cells were not modified at the lowest concentrations mentioned above, but the rate tended to decrease at highest concentrations. In this experimental situation, the calculation of cell proliferation might be partly biased by the increased ratios of death and apoptosis.
In vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al Third, flow cytometry quantitation of cell population distribution indicated that phenotypes were not altered by the CAs. Indeed, the percentage of CD56+ cells remained high (more than 78%) throughout cell expansions.
Finally, the differentiation capacity of loaded myogenic cells was assessed by the formation of myotubes in differentiation conditions, and calculation of fusion indexes. In comparison with unloaded cells, the fusion indexes obtained for all the Gd-DTPA or SPIO loading doses were not statistically different. Indeed, direct loading of both CAs did not alter the differentiation ability of myoblasts.
On the basis of these results, we chose 25 and 40 mM of Gd-DTPA and 100-500 mg ml À1 of SPIOs and performed a preliminary feasibility assay in vivo. Its aim was to determine the concentration of each CA that would provide sufficient contrast for NMR detection while labeling comparable areas at injection sites. Loaded human cells were injected into mouse muscles and NMR images were obtained and analyzed on the same day. We selected the concentrations of 25 mM Gd-DTPA and 100 mg ml
SPIOs for further in vivo experiments (see Table 1 ).
The ranges of CA concentrations, determined to be safe in vitro, then in vivo in this study, have also been proven non-toxic and effective in other studies using SPIOs 21, 28, 29 or Gd chelate. 20 
NMR imaging characterization of the injection rejection paradigm in mouse muscle
Contrast in NMR images is governed by various endogenous processes such as inflammation, on top of which CA relaxivity properties are further added. We first showed that the lesion caused by the surgical act induced only slight and transient modifications of muscle NMR signal. Mouse leg muscles were injected with a phosphate-buffered saline (PBS) solution that was visible only as hyperintensities on T2 maps, and had totally disappeared at D6 (data not shown). The monitoring of C57BL/6 mice legs injected with unlabeled human myoblasts demonstrated no visible changes on sectional T1-weighted images and T1 map. T2 maps, however, revealed the edema caused by the rejection process: we observed that T2 was increased by 19 ± 5.5 ms at the injection site as compared with normal tissue at D4 (Figure 1 ) and progressively decreased within the next 3 weeks.
NMRI follow-up of grafted SPIO-labeled myoblasts and Gd-DTPA-labeled myoblasts in the mouse leg muscle Taking advantage of the rejection process of human myoblasts grafted into the leg muscle of immunocompetent mice, we tested the ability of SPIO and Gd-DTPA cell loading to monitor the graft status. The NMR scans of each animal were carefully inspected at D0. As expected at the selected concentrations, the legs that received Gd-DTPAloaded cells showed a hyperintense spot at the injection site on T1-weighted images. All those treated with SPIO label presented a hypointense area in the injected muscle. A few of the observed signal voids, evidently much larger than the injection site and probably resulting from an inhomogeneous distribution of the graft during the injection, were excluded from the study. 
Abbreviations: Gd, gadolinium; SPIO, superparamagnetic iron oxide particle. a b c Figure 1 Nuclear magnetic resonance (NMR) imaging of a C57BL/6 mouse leg 4 days after injection with unloaded human myoblasts. T1-weighted imaging (a) or T1 mapping (c) did not show any change all along the experiment. T2 maps (b) indicated the inflammation site (white arrow), which covered the widest area on D4 and tended to disappear in 3 weeks. This phenomenon had to be taken into account when analyzing images of labeled human myoblasts injected into muscles.
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Among the set of T1-weighted transversal images obtained on D0 for each animal leg, we chose a representative slice and monitored the time course of the graft signal at each time point of the experiment: D1, D4, D6, D8, D11, D14, D21 and 3 months posttransplantation (illustrated on Figures 2b and c) . We performed a quantitative analysis of the T1-weighted images by monitoring the following three parameters: the size N of the labeled area, the contrast C between surrounding muscle and labeled area, and finally the product C Â N, which accounts for the two phenomena.
The size N of the labeled area was measured on T1-weighted images and normalized to the value at D0 (Figure 3a ). For Gd-DTPA label, we noted a linear In vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al decrease (N ¼ À0.07+0.95 day; R 2 ¼ 0.98) between D0 and D14 and a total disappearance on D21. The size of the SPIO-labeled area showed an initial increase of 23% between D0 and D1, it then slowly diminished to 50% of its initial size at D14 and later remained stable over the rest of the experiment. The time to half label size was t 1/2N ¼ 39.5±42 days for SPIO and t 1/2N ¼ 5.7±3 days for Gd-DTPA.
The contrast between SPIO label and muscle was very stable over the 3 months of the experiment, whereas the contrast between Gd-DTPA label and muscle decreased and totally disappeared within 3 weeks (Figure 3b ).
Right from D1, the contrast between Gd-DTPA label and muscle was only +58% of its value at D0. It then linearly decreased until D21 (C ¼ 0.05+0.83 day; R 2 ¼ 0.89). The time to 50% decrease of the initial contrast value was t 1/2C ¼ 85 ± 19 days for SPIO and t 1/2C ¼ 5 ± 4 days for Gd-DTPA.
Finally, we also assessed the possibility of monitoring the graft by the product C Â N for Gd-DTPA and SPIO labels (Figure 3c ), and the time to half the initial value was t 1/2CN ¼ 11.2±25 days for SPIO and t 1/2CN ¼ 1.6±1.2 days for Gd-DTPA.
Because of the strong T2 relaxivity of SPIOs, T2 mapping systematically showed a dark spot where SPIOlabeled cells were grafted, whereas the milder T2 shortening due to the presence of Gd-DTPA was visible only on D1. The increase in T2 induced by the local inflammatory response competed with Gd-DTPA-induced T2 relaxation in such a way that the latter was masked, as confirmed by measurements on unlabeled cell injection sites ( Figure 1 ) and computer simulations.
On the other hand, Gd-DTPA T1 shortening effect was visible on T1 maps in spite of the inflammation. We measured the difference over time in longitudinal relaxation rate r 1 ¼ 1/T1 of the labeled area relatively to the normal tissue, which decreased from Dr 1 ¼ 0.47 s -1 on D1 to Dr 1 ¼ 0.21 s -1 on D21 (over an area reduced to 38% of its initial size). Unlike T2 variations, T1 variations of unloaded cells were below our detection limit and consequently did not affect T1 measurements of Gd-DTPA-loaded cells.
Finally and most importantly, the time courses of all the parameters that we studied were significantly different between SPIO-and Gd-DTPA-labeled legs (Pp0.05) and showed that Gd-DTPA label disappearance had occurred within 3 weeks after the injection of human myoblasts in host tissue, whereas SPIO label had reached a plateau by then and was still visible after 3 months.
The fate of human myoblasts transplanted into immunocompetent mouse muscle
After NMR imaging, batches of animals were immediately killed. Their muscles were processed to identify total nuclei (4,6-diamidino-2-phenylindole (DAPI) staining), the laminin delineating the endomysial and the muscle fiber compartments, and the human-specific nuclear lamin A/C (Figure 2a) . The latter was selected to identify human nuclei on fusion with mouse muscle fibers, and to witness the formation of hybrid host-donor structures, at the time when human cellular elements are diluted within the large mouse muscle cytoplasm. SPIOs, if any, were detected in blue with Prussian blue staining (Figure 2d ).
On the injection day, the presence of human cells was confirmed by the detection of numerous nuclei (DAPI) colocalized with human lamin A/C staining. These pockets of cells were located in the endomysium, as delineated by laminin staining. On serial sections, Prussian blue staining confirmed the presence of numerous ferrite nanoparticles inside the injected cells. At this early time, most nuclei were of human origin, and the inflammation process was not extensive yet.
On days 1 and 2, inflammatory cells, identified by DAPI staining and devoid of human-specific lamin A/C staining, extensively invaded the injection sites. Already, In vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al nuclei were still observed. Of note, Prussian blue staining illustrated the presence of ferrite nanoparticles in the endomysium, and in some rare mouse muscle fibers (Figure 4g-h ).
As expected, 30 the complete rejection of human myoblasts was observed 8 days after injection. The injection sites were identified by the presence of numerous nuclei not expressing human antigens. Human myoblasts were then considered as eliminated by the inflammatory cells. We did not observe differences in rejection kinetics between legs injected with SPIOloaded, Gd-DTPA-loaded or unloaded human cells. This observation was confirmed on D14.
Prussian blue staining confirmed the presence of a high concentration of iron along aponevrotic sheet between fibers at D95, which was in good agreement with the persistence of the negative NMR contrast over time, and findings by Cahill et al.
22
Discussion
In this study, we showed that sufficient contrast can be generated by Gd chelate and iron oxide CAs preloading of myoblasts, in media containing 25 mM Gd-DTPA and 100 mg ml À1 ferumoxide, respectively, to detect approximately 10 6 cells immediately after transplantation into skeletal muscle. No significant toxicity was associated with the CA concentrations needed to obtain a measurable contrast on NMR images. High cell mortality, which is the rule with direct intramuscular injection of myoblasts, releases CA into the interstitium. Low molecular weight soluble Gd chelates are more or less rapidly washed out, with a time lag that remains to be explained. A significant proportion of the released iron oxide particles are captured by neighboring or inflammatory cells that reside locally for very long periods of time. The long-term remanence of SPIO-induced hypointensities is no guarantee of transplanted cell survival. In contrast, there is a very high risk of seeing inflammatory cells, secondarily attracted on site. As a consequence, SPIO loading of transplanted cells is valid and will yield interpretable results only when imaging is performed immediately after injection to map the initial distribution volume. Long-term studies will be biased by unspecific label transfer to macrophages, the severity of the problem being directly proportional to grafted cell mortality. It might be less severe when cells are injected intravascularly. In this study, we addressed only the question of confounding remanence of contrast and poor specificity of cell labeling with SPIOs. One also needs to investigate the long-term follow-up and sensitivity of cell detection with Gd chelates, for example, in immunodeficient SCID mice. A slow progressive release of Gd chelate, by the same pinocytosis processes that resulted in CA intracellular accumulation, is likely to occur, with kinetic characteristics that remain to be determined.
There is an important lesson to draw from this study. Potentially therapeutic counts of transplanted cells can be visualized by in vivo NMR imaging equally well after loading with Gd chelates or SPIOs. These results were obtained without the use of cell uptake facilitating factors and for intracellular concentrations of CAs that had no detectable deleterious effect on cell viability. In protocols where cell detection sensitivity is not a critical issue, Gd chelate loading is an alternative for in vivo cell imaging, which has been somewhat overlooked so far, with only seven published papers over the last 3 years 20,31-36 versus more than 45 using SPIOs and USPIOs.
There is much more than feasibility, safety and convenience considerations to encourage the investigators to opt for Gd chelate loading in many conditions. Although the extent of labeling was initially comparable with the two CAs, a crucial observation was the very divergent outcome of Gd chelate and SPIO labeling as monitored by in vivo NMR imaging. The labeled area shrank at a slower rate after SPIO loading than after Gd chelate loading. Although Gd labeling totally disappeared, it remained an SPIO-labeled area throughout the 90 days of follow up. This area was stable with a surface corresponding to approximately 40% of the initial zone. In the caricatured model of acute immune rejection that we had chosen, long-term remanence of SPIOs was a proof of their release from myoblasts and re-uptake by other cells. Very similar observations were made in both earlier and very recent publications. 22, 37 However, with our head-to-head comparison of labeling time courses obtained with two different classes of CAs and supplemented by histological confrontations at many time points, we clearly demonstrated the severity of the positive bias generated by SPIOs for the long-term monitoring of grafted cells. As SPIOs are avidly phagocytosed by reticulo-histiocytic cells, these compounds were initially developed for intravenous injections to map reticulo-histiocytic cell distribution. Hence, re-uptake by inflammatory cells of SPIOs released by dead labeled cells came as no surprise and was documented here by persistent positive Prussian blue staining of infiltrating cells in grafted muscles. Smaller size iron oxide complexes are less avidly taken up by phagocytic cells and choosing USPIOs instead would probably somewhat alleviate the particle recapture problem, at the expense of a lesser stability of the compound and its progressive catabolism over a few weeks time.
From a quantitative point of view, very large magnetic moments of SPIOs, which are responsible for their remarkable detection sensitivity, induce magnetic susceptibility changes at a relatively long distance and water spins dephase over a volume larger than the actual volume of labeled cells. These susceptibility effects are complex: they depend on the SPIO distribution in cells, on labeled cell dispersion and orientation with regard to the main magnetic field and their visualization also depends on the orientation of the imaging slice. This makes accurate localization and quantification of SPIO distribution quite difficult to achieve. In some instances, computer simulations and in vitro assessment of the labeled cells prior to injection can help, 38 but quantitation remains generally an unresolved issue.
As a consequence, the key message of this study is the following. Although a vast majority of studies of cell therapy monitoring by NMR imaging have been performed with SPIOs, the use of this CA is inadequate and will lead to erroneous conclusions in most instances, that is, each time a significant amount of grafted cells die in host tissue, which is the most frequent situation. Most investigators give preference to SPIO labeling because of the higher detection sensitivity with this CA. It remains legitimate to take advantage of this property to map therapeutic cell distribution but only immediately after
In vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al grafting or in the rare event that transplanted cell population is not to be prone to massive death. Rather unexpectedly, Gd chelate labeling remained visible up to 2 weeks after transplanted cell rejection. Reuptake by other cell types of Gd chelates released by dead transplanted cells is a priori an unlikely event because of the low molecular weight and the very short biological half-life of these molecules. Poor drainage of the interstitium due to local inflammation might facilitate uptake by reticulo-histiocytic cells or granulocytes, to an extent that remains to be determined. Another possible event is the fusion of human myoblasts with native muscle fibers and formation of hybrid fibers, the rejection of which is delayed and in which CA remained diluted but present for a longer period of time. However, such hybrid fibers were rare, as assessed by the immunohistochemical analysis. Also, some of the Gd chelate released by the many transplanted cells dying immediately after injection might diffuse into the cytoplasm of host muscle fibers that were damaged by needle trajectory but survived and subsequently resealed their sarcolemma. As a consequence, a quantity of Gd chelate would remain entrapped in host cells for an undetermined period of time. On the basis of measurements of Gd chelate persistence in electroporated muscle fibers, 39 it might be several weeks. After direct injection of Gd chelate into muscle (data not shown), local response was biphasic, most of the initial hyperintensity (70% of the initial product size contrast) disappeared during the next 20 h but a slow component of 30% persisted for weeks, which is in favor of the latter hypothesis. More conclusive evidence would be obtained by tracking the outcome of myoblasts loaded with Eu chelate by fluorescence microscopy. This would indicate whether any of this CA is present in inflammatory cells or in host muscle fibers. Their detection seems, however, to be considerably more complex on histological samples than on cultured cells.
As supported by our observations, we can at least assume that Gd chelate re-uptake is a problem of much lesser gravity than it is with SPIOs. The mechanisms responsible for the progressive and rapid decrease in Gd chelate label size and intensity cannot be fully elucidated at the moment. Of course, it is directly related to the loss of transplanted cells. For instance, the dramatic decrease in the number of positive pixels and in the relative contrast between D0 and D1 reflects the fact that at least 50% of grafted cells die within the first hours after injection. The time course of Gd labeling disappearance roughly follows the timing of an acute graft rejection, corroborated by the histological and immunohistological data collected in this study. A progressive release of CA from grafted cells by exocytosis can potentially contribute to the label fading, as suggested by our wash-out experiments in vitro (data not shown). Recently, Effectene-mediated transfection has proven to increase intracellular labeling longevity as compared with direct pinocytosis. 35 However, the long-term remanence in vivo of Gd chelate in electroporated muscles suggests a minor contribution from this mechanism. The dependence of CA release on loading procedures has to be investigated further. For instance, CA diffuses in cytoplasm after electroporation, and in perinuclear vesicles after pinocytosis. 24 Also, as recently pointed out, differential in vivo stability of commercial Gd chelates is another variable to be take into consideration for longer term studies, 40 but should have no role to play in the relative acute process we had been monitoring.
There are other issues to be considered when using Gd chelate loading to track grafted cells. Hyperintensities generated by Gd chelate might be difficult to distinguish from areas of fatty degeneration in diseased muscle. Ambiguities can be removed by adding chemically selective fat saturation modules to the imaging sequences. An angiographic effect by inflow of fast moving spins is frequent in T1-weighted sequences used to map Gd chelate-loaded cells. Discrimination is usually very simple based on the well-known topography of vasculature. If needed, as might be the case when therapeutic cells are administrated intravascularly, spatially selective saturation modules positioned upstream could be used to annihilate the blood signal.
Quantitative analysis of labeling size and intensity on NMR images was performed in this study. Yet, by no means does this imply that quantitative determination of grafted cell number or even of CA's concentration can be easily derived. But again, in most, if not all instances, quantitation issues would appear more problematic with SPIOs than with Gd chelates. This in our view represents a strong argument in favor of the latter. There are reports that claim quantitative estimates of ferrite-labeled cells. 41 Without any doubt, the size of the hypointensities generated by SPIOs is a function of the number of particles in the voxel. They also depend on local distribution of particles and on their orientation in the static magnetic field. Ferrite-induced hypointensities extend into adjacent voxels in a complex manner, also depending on the angulation with the magnetic field. All this makes the in vivo determination of SPIO concentration more than hypothetical as most of the controlling parameters are unknown and unquantifiable. It is unclear why the size of the SPIO spot increased between D0 and D1. The strong initial decrease in T2 relaxation associated with fluid injection and early inflammatory response certainly intervened. Labeled cell dispersion over a somewhat larger volume than the injection probably played a role as well. Their relative contributions would be difficult to determine precisely, knowing that, in addition, a large proportion of cells die during that specific period of time, and an undetermined fraction of released SPIOs entered lymphatic and venous circulations. In contrast, signal intensity changes induced by Gd chelate depend primarily on the CA concentration and relaxivity and hence would be more easily amenable to quantitation. However, intracellular relaxivities of Gd CAs cannot be determined in vivo and have to be extrapolated from in vitro measurements on biological samples. Relaxivity quenching at increasing concentrations of CAs has been identified after passive loading by unfacilitated pinocytosis. No such problem was detected when electroporation pulses were used to load cells. 20 Despite possible acute toxic effects associated with this technique, it should probably be given preference in protocols aiming at quantitative estimations. Labeling dilution by cell division or by fusion with unlabeled muscle fibers is often put forward as a drawback of cell detection based on prior loading with a CA. However, with Gd chelates, it should not significantly alter contrast as long as cells remain within the initial voxel after division or fusion.
In vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al Analysis of the negative contrast induced by SPIOs can also present some specific difficulties. Possible confusion with air bubble artifacts has been described, 42 but this seems easy to avoid if injection is carefully performed. In our numerous in vivo experiments, this problem was encountered only once. More frequently, iron susceptibility artifacts can prevent accurate localization of the graft and proper appreciation of response of surrounding tissues to treatment.
Hemorrhage, with the complex time course of signal abnormalities caused by red blood cell lysis and hemoglobin catabolism, is another potential confounding factor. 43 Some degree of bleeding might indeed occur as a consequence of the damages directly caused by injection. Such lesions would be similarly created during PBS injection as well but no abnormal signal was detected on NMR images taken in this experimental condition, which precludes a frequent contribution of hemorrhage to the observed NMR signal changes after intramuscular cell injection.
Inflammatory reaction caused by surgery and injection proved to be transient. After an injection of PBS, T2 maps showed only a discrete and focal increase in muscle at the injection site and T2 was back to normal values within less than 6 days. The inflammation caused by the immune reaction did not affect the detection of the graft on T1-weighted images. However, the Gd shortens T1 and T2, whereas inflammation increases T1, T2 and proton density. T1-weighted imaging is also sensitive to changes in T2 and proton density. The effects are opposite and may reduce or hide label contrast.
As just discussed above, all these sources of potential interferences had only a minor impact on our experimental results, the main significance of which remains unquestioned. Nevertheless, novel approaches might be appealing, with higher specificity and with a contrast depending exclusively on cell presence in situ and clearly separable from other coinciding events. Activatable CAs would be of great interest for the assessment of tissues heavily damaged by pathological changes. Extensive skeletal muscle remodeling develops in dystrophic muscles and it might be difficult to recognize dark or white spots generated by CA-labeled cells in a tissue that appears as a patchwork of hypo-, iso-and hyperintensities, corresponding to fibrosis, regenerating fibers and fatty replacement, respectively. These activatable NMR CAs exist and are known as CEST or PARACEST agents. 44 Contrast is generated by magnetization transfer between exchangeable protons in specific molecules and water. Although the principle of mechanism is very elegant, the preliminary results are encouraging, but these CAs are at an early stage of development and are not ready for use in preclinical studies. Besides, toxicity issues have yet to be addressed.
Another approach would be to use a reporter gene expression to identify cells transfected prior to transplantation. Plane scintigraphy and more recently single photon emission computed tomography (SPECT) and mSPECT tomography have been proposed to detect the sodium/iodide symporter (NIS) activity in cells transfected with the NIS gene for several months in rats. 45 Novel NMR reporter gene solutions might prove competitive, in particular the ones coding for bacterial membrane iron transporter. 46 When controlled by an inducible promoter, these transporters accumulate iron in eukaryotic cells and generate a contrast very similar to SPIOs, whereas the confounding risk of CA recapture and recycling by macrophages is largely prevented. It has also been proposed to introduce a reporter gene coding for polypeptides with CEST properties, such as polylysine. Proof of concept was recently reported. 47 However, all these novel developments, although very promising in terms of contrast improvement, raise a lot of questions about toxic and immunologic side effects. For these reasons, the standard, safe CAs studied here and clinically approved for i.v. injections long back, are likely to be the only ones to be considered for cell labeling in human protocols in the foreseeable future. Their use for these specific applications deserves to be further optimized.
Beyond survival and migration, therapeutic cell functionality is the key issue, and is very difficult to demonstrate in vivo. High-resolution functional NMR imaging has the potential to quantify fiber groups' contractility with velocity-encoding or -tagging techniques, to map local perfusion and blood oxygenation with arterial spin labeling and BOLD sequences. 48 It could be adapted to measure contractility, perfusion and oxygenation in areas with high therapeutic cell density detected by contrast enhancement on high-resolution anatomical images. Similarly, high-resolution chemical shift NMR spectroscopy can quantify the creatine pool, 49 an index of muscle metabolic activity, which could be used to evaluate energy metabolism in grafted areas as well. If successful, the combination of therapeutic cell topographical mapping and functional evaluation by NMR techniques would give NMR a definitive advantage over competing techniques for cell transplantation monitoring in vivo.
Materials and methods
Cell culture
Human muscle biopsies were obtained in agreement with the French Regulatory Health Authorities and our Ethics Committee from the Tissue Bank for Research of the French Association against Myopathies. The muscle fragments were minced and digested using liberase (1 h at 37 1C; Roche, Meylan, France), then trypsin-EDTA (0.05%, 20 min at 37 1C; Hyclone-Perbio, Brebieres, France). The cell suspension was filtered through 100-mm and then 40-mm cell strainers (Becton-Dickinson (BD), Le Pont de Claix, France) and pelleted. The cells were seeded in the proliferation medium containing 80% of modified MCDB medium (custom made by HyclonePerbio), 20% defined fetal bovine serum (HyclonePerbio), gentamicin (50 mg ml
À1
; Invitrogen, CergyPontoise, France), human recombinant bFGF (10 ng ml À1 ; R&D Systems, Lille, France) and dexamethasone (1 mM; Merck, Clermont-Ferrand, France). The cells were settled for 5 days, and then harvested by trypsinization and expanded until 80% confluence. Cells were amplified in cell factory (Nunc, Rochester, NY, USA). At each passage, one fraction was collected for phenotypical analysis (see below).
Cell loading with CAs
Here, 5 million cells were seeded in 75-cm 2 culture flasks. The following day, the required amounts of Gd-DTPA (Magnevist; Schering, Berlin, Germany) or SPIO (EndorIn vivo MRI of Gd-DTPA and SPIO-loaded myoblasts C Baligand et al em; Guerbet, Villepinte, France) were added to the culture medium to have final concentrations ranging from 10 to 80 mM and from 100 to 1000 mg ml À1 , respectively. After 24 h, loaded cells were harvested by trypsinization and suspended in PBS for in vitro measurements, or in PBS+0.5% of bovine serum albumin (Sigma, St Quentin Fallavier, France) for in vivo studies.
Cell analysis by cytofluorimetry: phenotyping, viability and apoptosis CD56 evaluation. The cells were incubated with phycoerythrin-coupled anti-CD56 antibody (clone NCAM 16.2, 1/5, 15 min at 4 1C; BD). Nonspecific labeling was evaluated using control isotype antibodies (IgG2b; BD). The CD56 phenotype was determined by fluorescence-activated cell sorting (FACS Calibur; BD) and recorded data (at least 10 4 events) were analyzed using the Cell Quest Software.
Cell viability. Cell viability of loaded cells was evaluated by propidium iodide exclusion (0.1 mg ml
À1
, 2 min at room temperature (RT); Sigma) and FACS analyses.
Cells apoptosis. Apoptosis of loaded cells was evaluated by annexin expression study. Briefly, cells were suspended in 100 ml annexin buffer (BD) containing annexin V-FITC antibody (BD) and incubated for 15 min at RT in the dark. Then, 100 ml of annexin buffer was added followed by data acquisition, which was performed immediately on a flow cytometer.
Proliferation assay. From the previously described cell cultures, 2 Â 10 4 myoblasts, loaded with or without CAs, were harvested and seeded into 12-well plates containing the proliferation medium. Cells from two wells were harvested at settled time points (D1, D2, D3, D4, D6 and D7) and counting was performed with a hematocytometer. Mean proliferation curves were established for each condition (n ¼ 3 for each time point).
Differentiation assay. In total, 50 000 loaded cells were seeded into 12-well plates. Differentiation was induced after 24 h by replacement of the proliferation medium by the differentiation medium containing DMEM medium (Invitrogen) and 10% horse serum (AbCys, Paris, France). At 5 days after the induction of differentiation, cells were permeabilized and fixed by cold methanol. The expression of fast MyHC in differentiated myotubes was assessed using monoclonal anti-fast MyHC antibody (clone MY32, 1/400, 1 h; Sigma) followed by a goat antimouse IgG (H+L) antibody (Alexa Fluor 568, 1/1000, 1 h; Invitrogen). The nuclei were labeled with DAPI (Vectashield+DAPI; AbCys). The presence or absence of labeled structures was then evaluated qualitatively using an inverted Olympus microscope equipped for fluorescence analysis. The fusion index was calculated on three microscopic fields at magnification Â 100 (at least 1000 nuclei counted).
In vivo experiments
The experiments complied with the Principles of Laboratory Animal Care. Transplantation experiments were performed in immunocompetent C57BL/6 mice (9 weeks old) (Charles River Laboratories, L'Arbresle, France). Animals were anesthetized with ketamine/ xylazine (30/15 mg kg À1 ). The skin was incised to expose the tibialis anterior muscle and 2 Â 10 6 myoblasts suspended in 10 ml PBS-BSA were slowly injected along the length of the tibialis anterior with a microsyringe (Hamilton, Bonaduz, Switzerland). This was repeated on both legs. In the first group A, 14 animals were injected in both legs with unloaded cells or with cells pre-loaded either with Gd-DTPA or SPIO. Nine were monitored by NMR during 3 months, and five were killed on D6, D8, D11 or D16 to compare with histological results. The other group B was set up with 20 animals, primarily to histologically assess cell survival following the graft. Animals received unloaded myoblasts in one of their legs and either Gd-DTPA-(n ¼ 14) or SPIO (n ¼ 6)-loaded myoblasts in the other leg. They were picked out on D0, D1, D2, D4, D6, D8, D11 or D14 for histology, immediately after NMR imaging.
NMR imaging
Mice underwent a series of NMR examinations immediately after cell injection (D0) (groups A and B) and repeatedly on D1, D4, D6, D8, D11, D14, D21 and 3 months post-transplantation (group A) or just before their killing (group B).
All acquisitions were performed on a 4T Bruker Biospec NMR spectrometer, equipped with a 20 cm diameter 200 mT m À1 gradient insert (Bruker BioSpin MRI GmbH, Ettlingen, Germany). Mice were anesthetized with 2% isoflurane (Forene; Abbot, Rungis, France) mixed with medical air delivered at 1.5 l min À1 and placed supine in a 28 mm inner diameter volume coil with quadrature polarization (Rapid Biomedical GmbH, Wü rzburg, Germany). A heating pad ensured a constant temperature during the experiment.
Axial T1-weighted spin echo images of the lower limbs were acquired. Imaging parameters were TR ¼ 150 ms, TE ¼ 5.7 ms, NEX ¼ 20, in-plane resolution ¼ 120 mm Â 120 mm, slice thickness ¼ 1.35 mm and inter-slice gap ¼ 2 mm. T1 was measured by saturation recovery RARE imaging (effective TE ¼ 8 ms; RARE factor ¼ 4; TR ¼ 71 ms; matrix size: 256 Â 128; in-plane resolution: 133 mm Â 137 mm; slice thickness ¼ 1.35 mm). T2 measurements were also systematically obtained by using a multiple spin-echo sequence (40 echoes, equally spaced between 7.4 and 296 ms; TR ¼ 2000 ms; matrix size: 256 Â 256; in-plane resolution: 120 mm Â 120 mm; slice thickness ¼ 1.35 mm).
Immunohistochemical analyses
Immediately after the NMR imaging session, mice were killed by overdose of anesthetics and muscles were taken and then snap frozen in nitrogen-cooled isopentane and serially sectioned (7 mm) using a cryostat. 
Data analysis
Registration between examinations was manually performed, based on the shape and the area of the tibia bone section.
T1-weighted. images were analyzed using the Image Sequences Analysis Tool of ParaVision (Bruker). To discriminate between pixels from labeled cells and pixels from muscle, we considered a confidence interval of 95% for muscle intensity. Thus, we defined the detection threshold as (S muscle +1.96 s.d.) for Gd-DTPA label and (S muscle À1.96 s.d.) for iron oxide label. S muscle is the mean intensity of muscle tissue surrounding the injection site and s.d. is the associated standard deviation. Number of pixels and signal intensity of the detected area were noted. The evolution of the graft was described by the following parameters:
The size N, the number of pixels detected as label, normalized to N at D0.
The relative contrast in absolute value,
ðS labeled pixels À S reference muscle Þ=ðN S reference muscle Þj;
normalized to C at D0. The product of the size by the relative contrast: N Â C. Half-life detection times of these parameters were extracted.
T1 and T2 maps were calculated using Matlab 7.1 (The Mathworks Inc., Natick, MA, USA) and Dr 1 and Dr 2 , the changes in the longitudinal and transversal relaxation rates of water proton, respectively, were evaluated. For calculation of T2 maps, the decay was assumed to be a single exponential. Noise was evaluated on the first magnitude image outside the object, and used to exclude pixels with low signal-to-noise ratio from the data set to fit according to SX7.6 Â M s.d. , where M s.d. is the background noise standard deviation, which is a stricter criterion than advised by Tofts. 50 
Statistics
All results are presented as mean ± s.d. Statistical analysis of NMR quantitative data were performed by using repeated measures analysis of variance (ANOVA), followed by Bonferroni comparison of means when appropriate. Toxicity assays on cell cultures were analyzed using ANOVA, then Tukey's test when appropriate. Pp0.05 was considered significant (NCSS 2001; NCSS, Kaysville, UT, USA).
